Imugene (original) (raw)

Imugene Ltd is a biotechnology company working in cancer immunotherapy. The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer, where the cancer is HER-2-positive. Imugene was planning a Phase Ib/II clinical study of HER-Vaxx in gastric cancer which it intended to initiate in 2016. Imugene stock is publicly traded on the Australian Securities Exchange (ASX).